Remdesivir: Drug has 'clear-cut' power to fight
coronavirus
coronavirus
Remdesivir cut the
duration of symptoms from 15 days down to 11 in clinical trial at hospitals
around the world.
duration of symptoms from 15 days down to 11 in clinical trial at hospitals
around the world.
The full details have
not been published, but experts said it would be a "fantastic result"
if confirmed, but not a "magic bullet" for the disease.
not been published, but experts said it would be a "fantastic result"
if confirmed, but not a "magic bullet" for the disease.
A drug would have the
potential to save lives, ease pressure on hospitals and allow parts of lockdown
to be lifted.
potential to save lives, ease pressure on hospitals and allow parts of lockdown
to be lifted.
Remdesivir was
originally developed as an Ebola treatment. It is an antiviral and works by
attacking an enzyme that a virus needs in order to replicate inside our cells.
originally developed as an Ebola treatment. It is an antiviral and works by
attacking an enzyme that a virus needs in order to replicate inside our cells.
The trial was run by
the US National Institute of Allergy and Infectious Diseases (NIAID) and 1,063
people took part. Some patients were given the drug while others received a
placebo (dummy) treatment.
the US National Institute of Allergy and Infectious Diseases (NIAID) and 1,063
people took part. Some patients were given the drug while others received a
placebo (dummy) treatment.
Dr Anthony Fauci who
runs the NIAID said: "The data shows remdesivir has a clear-cut,
significant, positive effect in diminishing the time to recovery."
runs the NIAID said: "The data shows remdesivir has a clear-cut,
significant, positive effect in diminishing the time to recovery."
He said the results
prove "a drug can block this virus" and were "opening the door
to the fact that we now have the capability of treating" patients.
prove "a drug can block this virus" and were "opening the door
to the fact that we now have the capability of treating" patients.
The impact on deaths
is not as clear cut. The mortality rate was 8% in people given remdesivir and
11.6% in those given a placebo, but this result was not statistically
significant, meaning scientists cannot tell if the difference is real.
is not as clear cut. The mortality rate was 8% in people given remdesivir and
11.6% in those given a placebo, but this result was not statistically
significant, meaning scientists cannot tell if the difference is real.
Prof Mahesh Parmar,
the director of the MRC Clinical Trials Unit at UCL, who has overseen the trial
in the EU, said:
the director of the MRC Clinical Trials Unit at UCL, who has overseen the trial
in the EU, said:
"Before this drug
can be made more widely available, a number of things need to happen: the data
and results need to be reviewed by the regulators to assess whether the drug
can be licensed and then they need assessment by the relevant health
authorities in various countries.
can be made more widely available, a number of things need to happen: the data
and results need to be reviewed by the regulators to assess whether the drug
can be licensed and then they need assessment by the relevant health
authorities in various countries.
"While this is
happening, we will obtain more and longer-term data from this trial, and other
one, on whether the drug also prevents deaths from Covid-19."
happening, we will obtain more and longer-term data from this trial, and other
one, on whether the drug also prevents deaths from Covid-19."
If a medicine can stop
people needing intensive care then the risk of hospitals being overwhelmed is
smaller, and there is less need for social distancing.
people needing intensive care then the risk of hospitals being overwhelmed is
smaller, and there is less need for social distancing.
Prof Peter Horby, from
the University of Oxford, is running the world's largest trial of Covid-19
drugs. He said: "We need to see the full results, but if confirmed this
would be a fantastic result and great news for the fight against Covid-19.
the University of Oxford, is running the world's largest trial of Covid-19
drugs. He said: "We need to see the full results, but if confirmed this
would be a fantastic result and great news for the fight against Covid-19.
"The next steps
are to get the full data out and work on equitable access to remdesivir."
are to get the full data out and work on equitable access to remdesivir."
The US
data on remdesivir has come out at the same time as a trial of the same drug in
China, reported in the Lancet medical
journal, showed it was ineffective.
data on remdesivir has come out at the same time as a trial of the same drug in
China, reported in the Lancet medical
journal, showed it was ineffective.
However, that trial
was incomplete because the success of lockdown in Wuhan meant doctors ran out
of patients.
was incomplete because the success of lockdown in Wuhan meant doctors ran out
of patients.
"These data are
promising, and given that we have no proven treatments yet for Covid, it may
well lead to fast-track approval of remdesivir for treatment of Covid,"
said Prof Babak Javid, a consultant in infectious diseases at Cambridge
University Hospitals.
promising, and given that we have no proven treatments yet for Covid, it may
well lead to fast-track approval of remdesivir for treatment of Covid,"
said Prof Babak Javid, a consultant in infectious diseases at Cambridge
University Hospitals.
"However, it also
shows that remdesivir is not a magic bullet in this context: the overall
benefit in survival was 30%."
shows that remdesivir is not a magic bullet in this context: the overall
benefit in survival was 30%."
Other drugs being
investigated for Covid-19 include those for malaria and HIV which can attack
the virus as well as compounds that can calm the immune system.
investigated for Covid-19 include those for malaria and HIV which can attack
the virus as well as compounds that can calm the immune system.
It is thought the
anti-virals may be more effective in the early stages, and the immune drugs
later in the disease.
anti-virals may be more effective in the early stages, and the immune drugs
later in the disease.
- remdesivir 专利,
- remdesivir pronunciation,
- remdesivir chicago,
- remdesivir and corona,
- remdesivir against corona,
- remdesivir antiviral drug hindi,
- remdesivir berita,
- remdesivir by study iq,
- remdesivir harapan baru,
- remdesivir bayly,
- historien bag remdesivir,
- remdesivir cnn news,
- remdesivir crux,
- remdesivir chicago university,
- remdesivir drug helps,
- remdesivir drug in hindi,
- remdesivir dr,
- remdesivir dawa,
- drbeen remdesivir,
- remdesivir estudo,
- antiviral remdesivir español,
- remdesivir noticias en español,
- remdesivir falla,
- gilead remdesivir,
- gilead remdesivir hindi,
- malaysia guna remdesivir,
- remdesivir hindi news,
- mike hansen remdesivir,
- remdesivir kya hota hai,
- remdesivir italy,
- remdesivir in chicago,
- remdesivir in corona,
- remdesivir pronunciation in hindi,
- remdesivir medicine in hindi,
- remdesivir production in india,
- remdesivir news in hindi,
- remdesivir vaccine in hindi,
- remdesivir jaime bayly,
- remdesivir kya hai,
- remdesivir kannada,
- kathleen mullane remdesivir,
- remdesivir drogas la rebaja,
- remdesivir medicine news,
- remdesivir news hindi,
- remdesivir tamil news,
- noticias del remdesivir,
- remdesivir on corona,
- remdesivir osmosis,
- remdesivir tv one,
- remdesivir university of chicago,
- cnn on remdesivir,
- historien om remdesivir,
- remdesivir peru,
- remdesivir cura para el coronavirus,
- remdesivir raoult,
- scishow remdesivir,
- remdesivir telugu,
- remdesivir trial failed,
- remdesivir tv9,
- remdesivir universidad de chicago,
- remdesivir video chicago,
- remdesivir cruz verde,
- remdesivir wion
Comments
Post a Comment